Skip to content

Acute Gastrointestinal Injury in Pediatrics

Acute Gastrointestinal Injury in Critically Ill Children in Pediatric Intensive Care Unit of Cipto Mangunkusumo Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05315245
Acronym
AGI
Enrollment
90
Registered
2022-04-07
Start date
2019-05-01
Completion date
2022-12-01
Last updated
2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Gastrointestinal Injury, Critical Illness, Gastrointestinal Failure

Brief summary

Critically Ill children may develop acute gastrointestinal injury secondary to severe inflammation.

Detailed description

Data collection from enrolled subjects including profile, laboratory examinations, inflammatory markers on day 1 and day 3, nutritional support and daily calorie intake, and finally outcome of the patient

Interventions

OTHERAGI

no intervention, only observation

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* critically ill pediatric patients receiving care at the PICU * presence of AGI (any degree)

Exclusion criteria

* patients who's body weight cannot be measured

Design outcomes

Primary

MeasureTime frameDescription
PELOD-2 scoretime of AGI diagnosis, day-1 PELOD-2 scoreThe Pediatric Logistic Organ Dysfunction (PELOD)-2 score is used to predict mortality and assess organ dysfunction. It consist of 10 components, assessing 5 organ dysfunction. The minimum score of PELOD-2 is 0 and the maximum score is 33. With the increasing organ dysfunction, the probability of death also increases.
mortalitydays from PICU admission date up to 28 days follow-upPICU mortality

Countries

Indonesia

Contacts

Primary ContactAntonius H Pudjiadi, MD, PhD
ahpudjiadi@gmail.com+628164812035
Backup ContactGryselda Hanafi, MD
gryseldahanafi@gmail.com087170113134

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026